| | | | | | | | | | |
| |
|
|
| Dockets Entered
On May 1, 2007
|
|
|
|
|
|
|
| |
|
|
| Docket #
|
| Title
|
|
|
|
|
|
|
| 1999V-0190
|
| Variance Laser Light Show LSD110XL MRAK10 & MRAK250
|
| |
|
|
| 2006D-0480
|
| Guidance for Industry on Complementary and Alternative Medicine Products and Their Regulation by the Food and Drug Administration
|
| |
|
|
| 2007D-0021
|
| Guidance for Industry; Advisory Committee Meetings: Preparation and Public Availability of Information Given to Advisory Committee Members
|
| |
|
|
| 2007P-0171
|
| Not delist U.S. patent 4,879,303 (the 303 patent) for Norvasc amlodipine besylate product
|
|
| |
|
| 1999V-0190
|
| Variance Laser Light Show LSD110XL MRAK10 & MRAK250
|
| |
|
|
| EXP 1
|
| Artistic Laser Productions
|
| Vol #:
|
| 1
|
| |
|
|
| 2006D-0480
|
| Guidance for Industry on Complementary and Alternative Medicine Products and Their Regulation by the Food and Drug Administration
|
| |
|
|
| C 125
|
| N. Kenyon
|
| Vol #:
|
| 10
|
| |
|
|
| C 126
|
| R. Brennan
|
| Vol #:
|
| 10
|
| |
|
|
| C 127
|
| L. Rambo
|
| Vol #:
|
| 10
|
| |
|
|
| C 128
|
| D. & J. Stogsdill
|
| Vol #:
|
| 10
|
| |
|
|
| C 129
|
| D. Molt
|
| Vol #:
|
| 10
|
| |
|
|
| C 130
|
| D. West
|
| Vol #:
|
| 10
|
| |
|
|
| C 131
|
| L. & P. Tinucci
|
| Vol #:
|
| 10
|
| |
|
|
| C 132
|
| A. Presley
|
| Vol #:
|
| 10
|
| |
|
|
| C 133
|
| M. Wilkins
|
| Vol #:
|
| 10
|
| |
|
|
| C 134
|
| K. Kehoe
|
| Vol #:
|
| 10
|
| |
|
|
| C 135
|
| N. Hausler
|
| Vol #:
|
| 10
|
| |
|
|
| C 136
|
| Intentionally Anonymous
|
| Vol #:
|
| 10
|
| |
|
|
| C 137
|
| J. Smith
|
| Vol #:
|
| 10
|
| |
|
|
| C 138
|
| C. Harse
|
| Vol #:
|
| 10
|
| |
|
|
| C 139
|
| The Third Insight
|
| Vol #:
|
| 10
|
| |
|
|
| C 140
|
| A. Frantz
|
| Vol #:
|
| 10
|
| |
|
|
| C 141
|
| V. Jordan
|
| Vol #:
|
| 10
|
| |
|
|
| C 142
|
| L. Ashby
|
| Vol #:
|
| 10
|
| |
|
|
| C 143
|
| J. Hunter
|
| Vol #:
|
| 10
|
| |
|
|
| C 144
|
| M. Tudor
|
| Vol #:
|
| 10
|
| |
|
|
| C 145
|
| B. Alger
|
| Vol #:
|
| 10
|
| |
|
|
| C 146
|
| S. Laubmeier
|
| Vol #:
|
| 10
|
| |
|
|
| C 147
|
| C. Zegan
|
| Vol #:
|
| 10
|
| |
|
|
| C 148
|
| N. Withheld
|
| Vol #:
|
| 10
|
| |
|
|
| C 149
|
| L. Smith
|
| Vol #:
|
| 10
|
| |
|
|
| C 150
|
| S. Verhoorn
|
| Vol #:
|
| 10
|
| |
|
|
| C 151
|
| J. Curtis
|
| Vol #:
|
| 10
|
| |
|
|
| C 152
|
| A. N. R. O. Printing/Direct Mail
|
| Vol #:
|
| 10
|
|
| | | | | | | | |
|
| |
|
| C 153
|
| S. Meeting
|
| Vol #:
|
| 10
|
| |
|
|
| C 154
|
| C. Jordan
|
| Vol #:
|
| 10
|
| |
|
|
| C 155
|
| Georgetown University Medical Center-Department of Family Medicine
|
| Vol #:
|
| 10
|
| |
|
|
| C 156
|
| F. Jambrn
|
| Vol #:
|
| 10
|
| |
|
|
| C 157
|
| P. Jones
|
| Vol #:
|
| 10
|
| |
|
|
| C 158
|
| M. Wheeler
|
| Vol #:
|
| 10
|
| |
|
|
| EC 102
|
| Mr. Colin Waters
|
| Vol #:
|
| 6
|
| |
|
|
| EC 103
|
| Mrs. Perri Satterwhite
|
| Vol #:
|
| 6
|
| |
|
|
| 2007D-0021
|
| Guidance for Industry; Advisory Committee Meetings: Preparation and Public Availability of Information Given to Advisory Committee Members
|
| |
|
|
| C 1
|
| Sepracor Inc
|
| Vol #:
|
| 1
|
| |
|
|
| EC 1
|
| Mr. Clark VerHulst
|
| Vol #:
|
| 1
|
| |
|
|
| EC 2
|
| GlaxoSmithKline
|
| Vol #:
|
| 1
|
| |
|
|
| EC 3
|
| Merck Research Laboratories
|
| Vol #:
|
| 1
|
| |
|
|
| EC 4
|
| AstraZeneca LP
|
| Vol #:
|
| 1
|
| |
|
|
| EC 5
|
| Merck Research Laboratories
|
| Vol #:
|
| 1
|
| |
|
|
| EC 6
|
| Animal Health Institute
|
| Vol #:
|
| 1
|
| |
|
|
| EC 7
|
| AABB
|
| Vol #:
|
| 1
|
| |
|
|
| 2007P-0171
|
| Not delist U.S. patent 4,879,303 (the 303 patent) for Norvasc amlodipine besylate product
|
| |
|
|
| ACK 1
|
| FDA/DDM to Rothwell, Figg, Ernst & Manbeck, P.C
|
| Vol #:
|
| 1
|
| |
|
|
| CP 1
|
| Mylan Laboratories, Inc.
|
| Vol #:
|
| 1
|
|
|
